Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / SELL

SELL

Basics

Aliases:
This biomarker is also known as:
  • Leukocyte adhesion molecule 1,
  • lymph node homing receptor,
  • LSEL,
  • sL-selectin,
  • leukocyte-endothelial cell adhesion molecule 1,
  • pln homing receptor,
  • lymphocyte adhesion molecule 1,
  • LEU8,
  • leukocyte surface antigen Leu-8,
  • CD62 antigen-like family member L,
  • LAM1,
  • CD62L,
  • gp90-MEL,
  • CD62L antigen,
  • Leukocyte surface antigen Leu-8,
  • selectin L,
  • Leu-8,
  • TQ1,
  • Leukocyte-endothelial cell adhesion molecule 1,
  • Lyam-1,
  • Lymph node homing receptor,
  • LNHR,
  • L-selectin,
  • LYAM1,
  • PLNHR,
  • hLHRc,
  • LAM-1,
  • LECAM1,

View in BioMuta

Description…

sL-selectin, also known as SELL, is a cell surface adhesion molecule that belongs to a family of adhesion/homing receptors. SELL mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes and promotes initial tethering and rolling of leukocytes in endothelia, facilitating their migration into secondary lymphoid organs and inflammation sites. SELL contains a C-type lectin-like domain, a calcium-binding epidermal growth factor-like domain, and two short complement-like repeats. Alternatively spliced transcript variants have been found for this gene.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: SELL

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

SELL is a member of a 28 autoantibody (AAb) classifier that was developed with a sensitivity of 80.8% and a specificity of 61.6% (AUC=0.756). The 28 autoantibodies are potential biomarkers for breast cancer both individually and as members of the classifier.

Lung

Attributes

Phase: Two
QA State: Curated

Overview

SELL has not been identified previously in serum as a lung cancer biomarker and represents a novel finding in the aptamer proteomic technology study (Ostroff et al, 2010). A decreased level of SELL was seen in the serum of lung cancer patients compared to controls in this study.

Performance Comment

sL-selectin, also known as SELL, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.

Announcement